Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT04451824 Completed - Clinical trials for Overweight or Obesity

Examination of Circumferential Reduction

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The rationale for the selection of Outcome Measures is the compliance with FDA regulations as pertain to medical devices with a moderate level of risk of hazard leading to harm of the patient; firstly, the safety of the device in achieving the desired effect of its intended use when operated in the intended manner; and secondly, the effectiveness of the device in achieving its desired effect of its intended use in accordance with its proposed label and labeling. The rationale for the selection of the primary outcome measure is to satisfy the question of safety and effectiveness of the use of red-light exposure to reduce the circumference of overweight patients with a statistically significant Routine Use population size. Given that the Routine Use Data Analysis is open label and therefore not blinded, there is no need for a control group nor additional cohorts for varying levels of exposure and corresponding safety and/or effectiveness.

NCT ID: NCT04451616 Recruiting - Obesity Clinical Trials

Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome

PROG-FAM
Start date: July 3, 2020
Phase:
Study type: Observational [Patient Registry]

The main objective of the study is to assess the serum levels of progranulin and FAM19A5 protein in adults with metabolic syndrome.

NCT ID: NCT04450524 Completed - Obesity Clinical Trials

Changing Eating Behavior Using Cognitive Training

Start date: August 15, 2020
Phase: N/A
Study type: Interventional

Obesity is a global health problem. New and more efficient interventions are needed to overcome this disease. This randomized clinical trial aims to evaluate the effectiveness of changing eating behavior using cognitive training. These types of interventions have the role of creating new routines (unconsciously processed), in terms of healthy eating behaviors.

NCT ID: NCT04449432 Active, not recruiting - Clinical trials for Overweight and Obesity

Goals for Reaching Optimal Wellness: GROWell

Start date: December 14, 2020
Phase: N/A
Study type: Interventional

Despite the negative consequences to maternal-child health from women gaining too much weight during pregnancy, up to 62% of overweight and obese women gain more pregnancy weight than is recommended. This project will establish the efficacy of Goals for Reaching Optimal Wellness (GROWell), an mHealth tool for achieving appropriate pregnancy weight gain and promoting postpartum weight loss among women who enter pregnancy overweight or obese. GROWell will fill a gap in research and clinical care by providing a validated, standalone mHealth tool for weight control during pregnancy and postpartum, which is a currently lacking resource.

NCT ID: NCT04447261 Completed - Obesity Clinical Trials

A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

Start date: June 30, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days. Secondary objectives are the exploration of pharmacokinetics (PK) of BI 1356225 after multiple oral dosing. Additionally, the relative bioavailability (BA) of midazolam and celecoxib in the presence and absence of BI 1356225 will be evaluated

NCT ID: NCT04440345 Completed - Clinical trials for Overweight or Obesity

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Start date: June 16, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.

NCT ID: NCT04437550 Completed - Clinical trials for Overweight and Obesity

Effects of Exercise Intensity on Energy Intake, Appetite and Enjoyment in Overweight and Obese Females

Start date: January 2016
Phase: N/A
Study type: Interventional

Interval exercise involves short bouts of high intensity exercise interspersed with periods of lower intensity exercise. The benefit is that a shorter total duration of exercise may be required to achieve cardiovascular benefits similar to or even superior to traditional longer bouts of steady state endurance exercise. However how this type of exercise affects appetite and energy intake, particularly in overweight and obese females is not well known. This study involves two trials of exercise, one at high intensity and one at low intensity, followed by a buffet lunch, in overweight and obese females.

NCT ID: NCT04434534 Recruiting - Clinical trials for Overweight and Obesity

Effect of Açaí Juçara Consumption on Endothelial Function and Arterial Stiffness

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

This study evaluates the consumption of Açaí Juçara pulp in endothelial function and arterial stiffness in overwheight and obese individuals. Half of participants will receive a hipocaloric diet and two Açaí Juçara pulps for daily consumption, while the other half will receive just a hipocaloric diet.

NCT ID: NCT04433273 Not yet recruiting - Clinical trials for Overweight and Obesity

Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage

Start date: May 2024
Phase: N/A
Study type: Interventional

The vestibular system which is responsible for balance and equilibrium constitutes our sixth sense. Metabolic Syndrome is a constellation of metabolic abnormalities characterized by obesity, insulin resistance (diabetes mellitus), hypertension, and dyslipidemia. It is generally agreed that a combination of three or more of the following components must be present: large waist circumference, elevated triglyceride, decreased high-density lipoprotein (HDL) cholesterol raised blood pressure, and elevated fasting blood sugar (FBS). Sirtuin 1 (SIRT1) is one of seven mammalian orthologs of the yeast protein silent information regulator. It is a conserved NAD-dependent protein deacetylase that decreases in cells that have high insulin resistance. In vivo, insulin resistance and metabolic syndrome were associated with low SIRT1 gene and protein expression. SIRT1 plays an important role to stimulate AMPK in improving mitochondrial function both in-vitro and in-vivo. Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) is a key factor in regulating energy metabolism, placing it at the center stage in studies of diabetes and related metabolic disorders like metabolic syndrome. It was reported that over a period of 6 weeks regular vestibular rehabilitation exercises caused an increase in the expression of SIRT1. The sleep inducing effects of vestibular stimulation is well known. Earlier studies reported improvement in the scores of Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) followed by the vestibular stimulation. Hence, we hypothesize that vestibular stimulation will lead to up-regulation of both SIRT1 and AMPK.

NCT ID: NCT04430465 Completed - Overweight Clinical Trials

Effects of Wholegrains on Children's Health (KORN)

Start date: September 3, 2020
Phase: N/A
Study type: Interventional

KORN investigates the effects of wholegrain oat and rye intake on health and cognitive wellbeing in children with overweight.